Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

Alnylam has the FDA approval it sought for Amvuttra in a form of cardiomyopathy associated with rare disease ATTR amyloidosis ...

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. | Despite growing competition ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

Amvuttra is entering the ATTR cardiomyopathy market behind products from Pfizer that have become the standard of care and a BridgeBio Pharma drug approved last fall. But Amvuttra introduces a new ...

Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...

The ATTR-CM market has grown more competitive following Food and Drug Administration approval of BridgeBio's Attruby in November 2024. There is also competition from Pfizer's Vyndaqel and Vyndamax ...

The ATTR-CM market is currently dominated by Pfizer’s Vyndaqel/Vyndamax (tafamidis) and BridgeBio’s recently approved Attruby (acoramidis). Unlike these medications, which are TTR stabilisers ...

Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major ...